MarketCap
Facebook
X
TelegramPRA Health Sciences, Inc. Revenue 2011-2025 | PRAH
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue PRA Health Sciences, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 3.18 B | 3.07 B | 2.87 B | 2.26 B | 1.81 B | 1.61 B | 1.46 B | - | 700 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.18 B | 700 M | 2.12 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
2.97 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Brainsway Ltd.
BWAY
|
41 M | $ 18.65 | -3.72 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
508 M | $ 20.72 | -3.9 % | $ 223 M |  China |
 |
Co-Diagnostics
CODX
|
6.81 M | $ 0.22 | -4.64 % | $ 6.46 M | USA |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
Castle Biosciences
CSTL
|
332 M | $ 39.14 | -0.65 % | $ 1.09 B | USA |
 |
Danaher Corporation
DHR
|
23.9 B | $ 230.35 | - | $ 168 B | USA |
 |
DarioHealth Corp.
DRIO
|
20.4 M | $ 10.65 | 6.03 % | $ 302 M | Israel |
 |
BioNano Genomics
BNGO
|
30.8 M | $ 1.5 | -1.45 % | $ 1.91 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M |  Britain |
 |
Exact Sciences Corporation
EXAS
|
2.76 B | $ 101.58 | - | $ 18.8 B | USA |
 |
DexCom
DXCM
|
3.62 B | $ 67.97 | 0.59 % | $ 26.2 B | USA |
 |
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
283 M | $ 26.61 | -0.41 % | $ 805 M | USA |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
6.79 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
280 M | $ 19.07 | -2.1 % | $ 1.03 B | USA |
 |
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | USA |
 |
Anixa Biosciences
ANIX
|
210 K | $ 3.16 | -1.25 % | $ 101 K | USA |
 |
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | USA |
 |
IQVIA Holdings
IQV
|
15.4 B | $ 226.1 | -0.36 % | $ 41 B | USA |
 |
Guardant Health
GH
|
739 M | $ 102.18 | -0.78 % | $ 12.5 B | USA |
 |
Myriad Genetics
MYGN
|
838 M | $ 6.35 | -2.08 % | $ 575 M | USA |
 |
ENDRA Life Sciences
NDRA
|
6.17 K | $ 4.84 | -4.69 % | $ 2.6 M | USA |
 |
Neogen Corporation
NEOG
|
895 M | $ 7.22 | 1.19 % | $ 1.57 B | USA |
 |
Aspira Women's Health
AWH
|
8.18 M | - | -6.19 % | $ 10.5 M | USA |
 |
National Research Corporation
NRC
|
149 M | $ 18.59 | -0.38 % | $ 456 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
18 B | $ 27.27 | 0.59 % | $ 20 B |  Niderland |
 |
Personalis
PSNL
|
84.6 M | $ 8.15 | 0.12 % | $ 483 M | USA |
 |
Quidel Corporation
QDEL
|
1.66 B | $ 29.14 | -0.55 % | $ 1.23 B | USA |
 |
Illumina
ILMN
|
4.37 B | $ 134.01 | -0.7 % | $ 21.3 B | USA |
 |
Charles River Laboratories International
CRL
|
4.05 B | $ 203.03 | -0.26 % | $ 10.4 B | USA |
 |
RadNet
RDNT
|
1.83 B | $ 73.16 | 0.01 % | $ 5.34 B | USA |
 |
Soleno Therapeutics
SLNO
|
1.45 M | $ 47.85 | 0.42 % | $ 1.92 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.87 B | $ 175.51 | -0.26 % | $ 19.5 B | USA |
|
Biodesix
BDSX
|
71.3 M | $ 6.6 | -3.19 % | $ 856 M | USA |
 |
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
13 B | $ 253.06 | -0.33 % | $ 21.2 B | USA |
 |
ICON Public Limited Company
ICLR
|
5.48 B | $ 182.53 | -0.17 % | $ 15.1 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
3.9 B | $ 683.64 | -0.7 % | $ 56.4 B | USA |
 |
Lantheus Holdings
LNTH
|
1.53 B | $ 67.05 | 0.51 % | $ 4.64 B | USA |
 |
Mettler-Toledo International
MTD
|
3.87 B | $ 1 411.78 | -0.59 % | $ 30 B |  Schweiz |